somatostatin


Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.
Related to somatostatin: Octreotide

somatostatin

 (SRIF, SS) [so″mah-to-stat´in]
a cyclic tetradecapeptide hormone and neurotransmitter that inhibits the release of peptide hormones in many tissues. It is released by the hypothalamus to inhibit the release of growth hormone (GH, somatotropin) and thyroid stimulating hormone (TSH) from the anterior pituitary; it is also released by the delta cells of the islets of Langerhans in the pancreas to inhibit the release of glucagon and insulin and by the similar D cells in the gastrointestinal tract.

so·ma·to·stat·in

(sō'mă-tō-stat'in), [MIM*182450]
A tetradecapeptide capable of inhibiting the release of somatotropin by the anterior lobe of the pituitary gland; somatostatin has a short half-life; it also inhibits the release of insulin, glucagon, and gastrin. Used in the treatment of acromegaly, gigantism, and pancreatic tumors.
[somatotropin + G. stasis, a standing still, + -in]

somatostatin

(sō-măt′ə-stăt′n, sō′mə-tə-)
n.
A polypeptide hormone produced chiefly by the hypothalamus that inhibits the secretion of various other hormones, such as somatotropin, glucagon, insulin, thyrotropin, and gastrin.

so·ma·to·stat·in

(sō'mă-tō-stat'in)
A tetradecapeptide capable of inhibiting release of somatotropin, insulin, and gastrin.
Compare: bioregulator
Synonym(s): growth hormone-inhibiting hormone, somatotropin release-inhibiting hormone.
[somato- + G. stasis, a standing still, + -in]

somatostatin

a hormone of the hypothalamus that inhibits the release of growth hormone from the pituitary gland.

so·ma·to·stat·in

(sō'mă-tō-stat'in) [MIM*182450]
Tetradecapeptide capable of inhibiting release of somatotropin by anterior lobe of pituitary gland.
[somatotropin + G. stasis, a standing still, + -in]
References in periodicals archive ?
Hicks, "High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours," Journal of Medical Imaging and Radiation Oncology, vol.
Somatostatin and Somatostatin Receptors in Neuroendocrine Tumors
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?.
Efficacy and safety of an oral somatostatin DNA vaccine without antibiotic resistance gene in promoting growth of piglets.
DOTATATE is therefore a derived somatostatin analogue peptide which is an abbreviated form of [DOTA0,Tyr3]-octreotate where Tyr3-octeotide is the synthetic octreotide analogue.
Somatostatin receptors can also be utilized as a target for peptide receptor radionuclide therapy (PRRT).
Considering that immunostaining for somatostatin receptor 2 antibody was scored as 3 (circumferential membranous reactivity in >50% of tumor cells), subcutaneous octreotide therapy was started at a dose of 100 [micro]g/day (Figure 4).
As for the treatment of AUGIB, 508 (61.5%) patients underwent endoscopic therapy, 20 (2.4%) patients underwent Sengstaken Blackmore tube placement, 750 (90.8%) patients received somatostatin and/or octreotide, 544 (65.9%) patients received blood transfusion, 813 (98.4%) patients received PPIs, and 8 (1.0%) patients underwent surgery.
Somatostatin is produced by D cells located in the stomach, the small and large intestine, and also the pancreas [27].
She developed gastrointestinal decompression and was given somatostatin and parenteral nutrition support basic therapy.
Total parenteral nutrition (TPN) and intravenous administration of somatostatin at a dose of 6 mg/day via an infusion pump was started the day after the intervention.
Somatostatin is ubiquitously expressed throughout the body and can be found in many tissues, e.g., the stomach, the intestine, and the pancreatic islets, but also in the central nervous system (1).

Full browser ?